Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Gasparini

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Science Translational Medicine|April 2, 2025
Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trialBaltazar Gomez-Mancilla, Kenneth M Dürsteler, Marc Vogel, et al.
Cell Reports|June 1, 2022
Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer's diseaseRahul Dhandapani, Marilisa Neri, Mario Bernhard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2011
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trialsDaniela Berg, Jana Godau, Claudia Trenkwalder, et al.
Nature Reviews. Drug Discovery|December 9, 2017
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndromeElizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, et al.
Science Translational Medicine|January 7, 2011
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056Sébastien Jacquemont, Aurore Curie, Vincent des Portes, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Science Translational Medicine|April 2, 2025
Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trialBaltazar Gomez-Mancilla, Kenneth M Dürsteler, Marc Vogel, et al.
Cell Reports|June 1, 2022
Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer's diseaseRahul Dhandapani, Marilisa Neri, Mario Bernhard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2011
AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trialsDaniela Berg, Jana Godau, Claudia Trenkwalder, et al.
Nature Reviews. Drug Discovery|December 9, 2017
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndromeElizabeth M Berry-Kravis, Lothar Lindemann, Aia E Jønch, et al.
Science Translational Medicine|January 7, 2011
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056Sébastien Jacquemont, Aurore Curie, Vincent des Portes, et al.
Pageof 7